This Article Full Text Full Text (PDF) All Versions of this Article: 48/2/198    most recent 01.HYP.0000231339.51310.b3v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cutler, J. A. Search for Related Content PubMed PubMed Citation Articles by Cutler, J. A. Related Collections Type 2 diabetes Glucose intolerance Clinical Studies Epidemiology Related Article

(Hypertension. 2006;48:198.)
© 2006 American Heart Association, Inc.

Editorial Commentaries

Thiazide-Associated Glucose Abnormalities: Prognosis, Etiology, and Prevention

Is Potassium Balance the Key?

Jeffrey A. Cutler

From the Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md.

Correspondence to Jeffrey A. Cutler, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, 6701 Rockledge Dr, MSC 7938, Bethesda, MD 20892. E-mail CutlerJ@nhlbi.nih.gov

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Thiazide diuretics have been recommended as the preferred class of antihypertensive (AHT) drugs for initial therapy and for inclusion in a regimen of multiple drugs.¹ This recommendation is based on 4 decades of randomized clinical events trials with placebo (or usual care) comparators, meta-analyses of such trials, and active-controlled trials, including the very large Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT).^2,3 In the latter, treatment beginning with the thiazide-like diuretic chlorthalidone reduced the risk for major coronary events (the primary outcome) similar to treatment based on representatives of newer drug classes (amlodipine, doxazosin, and lisinopril); diuretic-based treatment was more effective at preventing heart failure, and in some comparisons, other cardiovascular disease (CVD) events.

However, in ALLHAT mean fasting blood glucose (FBG) and incident diabetes mellitus (IDM) were slightly but significantly increased in the chlorthalidone compared with the other arms.³ Although the design precluded distinguishing between a benefit of the alternate drugs (especially lisinopril) and an adverse effect of the diuretic, previous evidence suggested that thiazides can cause dysglycemia (impaired glucose tolerance, impaired fasting glucose, or diabetes).⁴ One point about the ALLHAT results that has not received enough emphasis is that if the calcium channel blocker is taken as metabolically neutral, the 4-year IDM rates in the diuretic and calcium channel blocker arms (11.6% and 9.8%, respectively) imply that 83% of IDM occurring in association with thiazide use is not because of the diuretic.

Nevertheless, based on the assumption that there is a direct relationship between thiazide . . . [Full Text of this Article]

Related Article:

Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review

Alan J. Zillich, Jay Garg, Sanjib Basu, George L. Bakris, and Barry L. Carter
Hypertension 2006 48: 219-224. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. T. Wright Jr, J. L. Probstfield, W. C. Cushman, S. L. Pressel, J. A. Cutler, B. R. Davis, P. T. Einhorn, M. Rahman, P. K. Whelton, C. E. Ford, et al. ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses Arch Intern Med, May 11, 2009; 169(9): 832 - 842. [Abstract] [Full Text] [PDF]

				R. M. Cooper-DeHoff, M. A. Pacanowski, and C. J. Pepine Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S28 - S34. [Abstract] [Full Text] [PDF]

				T. Shafi, L. J. Appel, E. R. Miller III, M. J. Klag, and R. S. Parekh Changes in Serum Potassium Mediate Thiazide-Induced Diabetes Hypertension, December 1, 2008; 52(6): 1022 - 1029. [Abstract] [Full Text] [PDF]

				B. L. Carter, P. T. Einhorn, M. Brands, J. He, J. A. Cutler, P. K. Whelton, G. L. Bakris, F. L. Brancati, W. C. Cushman, S. Oparil, et al. Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute Hypertension, July 1, 2008; 52(1): 30 - 36. [Full Text] [PDF]

				J. A. Cutler and B. R. Davis Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension Circulation, May 20, 2008; 117(20): 2691 - 2705. [Full Text] [PDF]

				J. I. Barzilay, B. R. Davis, J. A. Cutler, S. L. Pressel, P. K. Whelton, J. Basile, K. L. Margolis, S. T. Ong, L. S. Sadler, J. Summerson, et al. Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, November 13, 2006; 166(20): 2191 - 2201. [Abstract] [Full Text] [PDF]